AAV Vector Capsid Stoichiometry via Suboptimal Initiation Codons
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mammalian cell-based systems for producing adeno-associated virus (AAV) vectors face challenges in achieving high infectivity and scalability due to suboptimal expression of viral capsid proteins, leading to reduced yields and contamination risks, while insect cell systems require modifications to replicate the correct stoichiometry of VP1, VP2, and VP3 proteins for improved infectivity.
Innovation Solution
A nucleotide sequence is designed with a suboptimal initiation codon for VP1, such as CTG, and an expression control sequence including a Kozak consensus sequence to optimize the expression of AAV capsid proteins in insect cells, ensuring a higher ratio of VP1 to VP2, which enhances infectivity and production efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mammalian cell-based systems are used for AAV production, then infectivity is improved, but productivity is reduced
Solution Approach 1:
The invention changes the initiation codon parameter from the standard ATG to suboptimal codons (CTG, GTG, TTG, ACG) to reduce VP1 translation efficiency. This parameter change in the nucleotide sequence directly controls the stoichiometry of capsid proteins, achieving the desired VP1:VP2 ratio of 1:1 to 1:3 without requiring mammalian cell systems, thereby resolving the contradiction between infectivity and productivity.
2Productivity
If standard ATG initiation codon is used for VP1, then VP1 expression is high, but infectivity is reduced
Solution Approach 1:
Instead of using the standard optimal ATG initiation codon that maximizes VP1 expression, the invention inverts the approach by using suboptimal initiation codons (CTG, GTG, TTG, ACG) that reduce VP1 translation efficiency. This inversion of the codon choice directly addresses the contradiction by lowering VP1 levels to achieve proper stoichiometry and maintain infectivity, while still producing sufficient total capsid proteins.
3Productivity
If insect cell systems are used for AAV production, then productivity is improved, but manufacturing precision is reduced
Solution Approach 1:
The invention changes the initiation codon parameter in the nucleotide sequence to suboptimal codons (CTG, GTV, TTG, ACG) to control the translation efficiency of VP1. This parameter change compensates for the lack of splice acceptor site usage in insect cells, enabling precise control of capsid protein stoichiometry (VP1:VP2 ratio of 1:1 to 1:3) and achieving manufacturing precision comparable to mammalian systems while maintaining the productivity advantages of insect cells.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention relates to the production of adeno-associated viral vectors in insect cells. The insect cells therefore comprise a first nucleotide sequence encoding the adeno-associated virus (AAV) capsid proteins, whereby the initiation codon for translation of the AAV VP1 capsid protein is a non-ATG, suboptimal initiation codon. The insect cell further comprises a second nucleotide sequence comprising at least one AAV inverted terminal repeat (ITR) nucleotide sequence; a third nucleotide sequence comprising a Rep52 or a Rep40 coding sequence operably linked to expression control sequences for expression in an insect cell; and, a fourth nucleotide sequence comprising a Rep78 or a Rep68 coding sequence operably linked to expression control sequences for expression in an insect cell. The invention further relates to adeno-associated viral vectors with an altered ratio of the viral capsid proteins that provides improved infectivity of the viral particles.